Soma S. R. Banik, Xiaoxiang Deng, Edgar Davidson, Ulrich Storz, Benjamin J. Doranz
{"title":"用假面图和cdr扫描重新定义抗体专利保护","authors":"Soma S. R. Banik, Xiaoxiang Deng, Edgar Davidson, Ulrich Storz, Benjamin J. Doranz","doi":"10.1038/s41587-024-02549-w","DOIUrl":null,"url":null,"abstract":"Patent protection for therapeutic monoclonal antibodies requires a fundamental shift in strategy following Amgen v. Sanofi, which invalidated broad functional claims for antibody genera in the USA.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"43 2","pages":"170-174"},"PeriodicalIF":44.5000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41587-024-02549-w.pdf","citationCount":"0","resultStr":"{\"title\":\"Redefining antibody patent protection using paratope mapping and CDR-scanning\",\"authors\":\"Soma S. R. Banik, Xiaoxiang Deng, Edgar Davidson, Ulrich Storz, Benjamin J. Doranz\",\"doi\":\"10.1038/s41587-024-02549-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Patent protection for therapeutic monoclonal antibodies requires a fundamental shift in strategy following Amgen v. Sanofi, which invalidated broad functional claims for antibody genera in the USA.\",\"PeriodicalId\":19084,\"journal\":{\"name\":\"Nature biotechnology\",\"volume\":\"43 2\",\"pages\":\"170-174\"},\"PeriodicalIF\":44.5000,\"publicationDate\":\"2025-02-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.nature.com/articles/s41587-024-02549-w.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature biotechnology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://www.nature.com/articles/s41587-024-02549-w\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature biotechnology","FirstCategoryId":"5","ListUrlMain":"https://www.nature.com/articles/s41587-024-02549-w","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
在安进诉赛诺菲案（Amgen v. Sanofi）之后，治疗性单克隆抗体的专利保护需要从根本上改变策略。
Redefining antibody patent protection using paratope mapping and CDR-scanning
Patent protection for therapeutic monoclonal antibodies requires a fundamental shift in strategy following Amgen v. Sanofi, which invalidated broad functional claims for antibody genera in the USA.
期刊介绍：
Nature Biotechnology is a monthly journal that focuses on the science and business of biotechnology. It covers a wide range of topics including technology/methodology advancements in the biological, biomedical, agricultural, and environmental sciences. The journal also explores the commercial, political, ethical, legal, and societal aspects of this research.
The journal serves researchers by providing peer-reviewed research papers in the field of biotechnology. It also serves the business community by delivering news about research developments. This approach ensures that both the scientific and business communities are well-informed and able to stay up-to-date on the latest advancements and opportunities in the field.
Some key areas of interest in which the journal actively seeks research papers include molecular engineering of nucleic acids and proteins, molecular therapy, large-scale biology, computational biology, regenerative medicine, imaging technology, analytical biotechnology, applied immunology, food and agricultural biotechnology, and environmental biotechnology.
In summary, Nature Biotechnology is a comprehensive journal that covers both the scientific and business aspects of biotechnology. It strives to provide researchers with valuable research papers and news while also delivering important scientific advancements to the business community.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
